Novartis and the non-profit Medicines for Malaria Venture (MMV) have advanced a novel drug combination for malaria into a phase 3 programme, raising hopes of a regimen that could be used to treat ...

Supports future combination strategies involving other radiopharmaceuticals and antibody-drug conjugates (ADCs). An increasing number of radiopharmaceutical-based combinations are expected to emerge.